Q2 EPS Estimates for TScan Therapeutics Cut by HC Wainwright

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for TScan Therapeutics in a research report issued on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.32) for the quarter, down from their previous estimate of ($0.31). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.30) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($0.84) EPS and FY2028 earnings at ($0.30) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million.

TCRX has been the topic of several other research reports. Needham & Company LLC decreased their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research report on Wednesday, March 5th. Finally, Barclays dropped their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, TScan Therapeutics presently has an average rating of “Buy” and an average target price of $9.20.

TScan Therapeutics Trading Down 4.8 %

Shares of TScan Therapeutics stock opened at $1.98 on Monday. The stock has a 50 day moving average of $2.41 and a 200 day moving average of $3.99. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The firm has a market capitalization of $105.67 million, a price-to-earnings ratio of -1.87 and a beta of 0.91. TScan Therapeutics has a fifty-two week low of $1.82 and a fifty-two week high of $9.69.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds have recently bought and sold shares of the company. Heck Capital Advisors LLC purchased a new stake in TScan Therapeutics during the fourth quarter worth about $61,000. Woodline Partners LP increased its stake in TScan Therapeutics by 6.7% during the 4th quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock worth $352,000 after buying an additional 7,282 shares during the period. Squarepoint Ops LLC acquired a new stake in TScan Therapeutics during the 4th quarter worth approximately $59,000. Tang Capital Management LLC purchased a new position in TScan Therapeutics in the 4th quarter valued at approximately $358,000. Finally, Shay Capital LLC acquired a new position in shares of TScan Therapeutics in the fourth quarter worth $65,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.